Researchers at Stanford University have found that recombinant osteopontin (SPP1) protein reduces foreign body response (FBR) and thereby facilitates successful integration and function of implantable devices.
Stanford scientists have developed a novel hydrogel for long-term drug delivery of an Activator Protein 1 (AP-1) inhibitor for the prevention of post-surgical abdominal adhesion.